PATENT CLAIM ANALYSIS

Application Number: 16266305
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "249000"]

Abstract:
A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Claim (Index 18):
The Methotrexate composition according to  claim 14  wherein the citrate buffer system has a strength between 2 to 200 millimolar, and optionally between 2 to 20 millimolar.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 2.23077
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13733031', '15821242', '15019244', '12370794', '10553139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8131805625442916
- 35 USC 102 Novelty (BERT): 0.5638359002601196
- Combined Prediction Score: 0.7882460963158745
- Mean Citation Score: 369.87232000000006
- Max Citation Score: 441.5843
- Similarity Product: 388.6234502629399

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test